BTKi DOAC Bleeding Risk in CLL/SLL

BTKi DOAC Bleeding Risk in CLL/SLL

Es posible que algunos contenidos no estén disponibles en español.

Study Details

Full Title

Major Bleeding Risk with Concurrent Bruton Tyrosine Kinase (BTK) Inhibitors and Direct Oral Anticoagulants (DOACs) in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Retrospective Multicenter Cohort Study

Principal Investigator

Danielle
Brander

Protocol Number

PRO00120335

Enrollment Status

Open to Enrollment